A detailed history of Geode Capital Management, LLC transactions in Clene Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 921,556 shares of CLNN stock, worth $5.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
921,556
Previous 946,532 2.64%
Holding current value
$5.23 Million
Previous $407,000 18.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$0.31 - $0.44 $7,742 - $10,989
-24,976 Reduced 2.64%
921,556 $331,000
Q1 2024

May 13, 2024

BUY
$0.28 - $0.53 $93,702 - $177,366
334,653 Added 54.69%
946,532 $407,000
Q4 2023

Feb 13, 2024

BUY
$0.26 - $0.55 $6 - $13
25 Added 0.0%
611,879 $183,000
Q3 2023

Nov 13, 2023

BUY
$0.46 - $0.87 $136,758 - $258,651
297,300 Added 94.51%
611,854 $305,000
Q1 2023

May 15, 2023

BUY
$0.95 - $1.62 $79,561 - $135,673
83,749 Added 36.29%
314,554 $355,000
Q4 2022

Feb 13, 2023

BUY
$0.92 - $40.2 $8,844 - $386,482
9,614 Added 4.35%
230,805 $230,000
Q3 2022

Nov 14, 2022

SELL
$0.33 - $73.0 $3,217 - $711,677
-9,749 Reduced 4.22%
221,191 $619,000
Q2 2022

Aug 12, 2022

SELL
$2.1 - $4.12 $323,454 - $634,587
-154,026 Reduced 40.01%
230,940 $581,000
Q1 2022

May 13, 2022

SELL
$2.42 - $4.42 $6,413 - $11,713
-2,650 Reduced 0.68%
384,966 $1.52 Million
Q4 2021

Feb 11, 2022

SELL
$3.95 - $7.53 $71,577 - $136,451
-18,121 Reduced 4.47%
387,616 $1.59 Million
Q3 2021

Nov 12, 2021

BUY
$6.83 - $13.58 $22,825 - $45,384
3,342 Added 0.83%
405,737 $2.77 Million
Q2 2021

Aug 13, 2021

BUY
$6.98 - $13.33 $1.27 Million - $2.43 Million
182,040 Added 82.61%
402,395 $4.52 Million
Q1 2021

May 12, 2021

BUY
$6.39 - $16.3 $1.41 Million - $3.59 Million
220,355 New
220,355 $2.82 Million

Others Institutions Holding CLNN

About Clene Inc.


  • Ticker CLNN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,502,000
  • Market Cap $360M
  • Description
  • Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...
More about CLNN
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.